INTRODUCTION
============

As the number of hip arthroscopy procedures in the United States continues to increase at a dramatic rate \[[@hnx050-B1], [@hnx050-B2]\] with expanding indications \[[@hnx050-B3]\], there is growing interest in the improvement of postoperative pain management in these patients. Unfortunately, many patients experience significant pain in the immediate postoperative period, with several studies demonstrating moderate to severe pain in up to 90% of hip arthroscopy patients immediately following surgery \[[@hnx050-B4], [@hnx050-B5]\].

Postoperative pain management plays a central role in the quality of recovery, as even short intervals of acute pain have been shown to precipitate chronic pain, psychological distress and increased neuronal sensitization \[[@hnx050-B6]\]. These effects are obviously counterproductive in the expeditious recovery and rehabilitation of surgical patients. Furthermore, higher postoperative pain scores are associated with prolonged hospital stays and readmissions \[[@hnx050-B7], [@hnx050-B8]\]. Despite the well-known importance of postoperative pain management, there is little consensus regarding the best pain management strategy for hip arthroscopy patients.

One of the more common pain management modalities for hip arthroscopy is a peripheral nerve block in the perioperative period. Both femoral nerve blocks and fascia iliaca blockades, given either pre- or postoperatively, have demonstrated efficacy in decreasing pain and opioid use in the post-anesthesia care unit (PACU) following hip arthroscopy \[[@hnx050-B4], [@hnx050-B5], [@hnx050-B9]\]. However, peripheral nerve blocks are not without significant cost, as they require equipment costs, ultrasound procedural fees and potentially professional fees from an anesthesiologist. Although rare, regional nerve blocks also carry the risk of paresthesias, permanent nerve damage and postoperative falls \[[@hnx050-B10]\].

Consequently, there has been a growing interest among orthopaedic surgeons regarding local infiltration analgesia (LIA) as a pain management modality for a variety of orthopaedic procedures \[[@hnx050-B14]\]. Several studies have focused on the role of LIA in the setting of total knee arthroplasty and total hip arthroplasty \[[@hnx050-B24]\], where LIA has been shown to decrease pain and opioid consumption \[[@hnx050-B27], [@hnx050-B28]\]. There have been several studies which suggest a beneficial role of LIA in hip arthroscopy patients, though they have mostly focused on comparing different methods of LIA, which have included intra-articular injections \[[@hnx050-B29], [@hnx050-B30]\]. A recent study demonstrated that portal tract LIA led to significantly improved pain control as compared with a fascia iliac nerve block \[[@hnx050-B31]\].

The purpose of this retrospective study is to determine the efficacy of a single extracapsular injection of bupivacaine--epinephrine during hip arthroscopy in reducing the rate of elective postoperative femoral nerve blocks. Targeting the highly innervated \[[@hnx050-B29]\] hip capsule with LIA may improve postoperative pain control and reduce the necessity of other pain control modalities. We hypothesize that patients who receive a single extracapsular LIA injection during hip arthroscopy will receive fewer elective postoperative femoral nerve blocks as compared with patients who do not receive LIA. Secondary objectives of the study include measuring the immediate postoperative opioid consumption in patients treated with and without LIA.

MATERIALS AND METHODS
=====================

This was a single-center retrospective case--control study. With approval from the institutional review board, we identified 100 consecutive patients between the ages of 16 and 64 years who underwent a unilateral primary hip arthroscopy procedure between May 2015 and March 2016. The senior author began using the described LIA technique on all hip arthroscopy procedures starting in October 2015. Fifty patients from October 2015 to March 2016 were identified that received an extra-capsular LIA injection after repair of the hip capsule. Immediately after complete capsular closure, the spinal needle was arthroscopically placed in the space just anterior to the capsule ([Fig. 1](#hnx050-F1){ref-type="fig"}). Excess saline was suctioned out of the space followed by portal closure. After the portal closure, 20 ml of 0.25% bupivacaine--epinephrine (1 : 200 000) was injected into the extra-capsular space. Prior to this period, from May 2015 to September 2015, 50 hip arthroscopy patients that did not receive an LIA injection were identified. All procedures as well as the indications for the procedures were recorded. Patients were excluded for incomplete charting. Ultimately, 106 patients were reviewed with six charts being excluded due to incomplete charting. PACU opioid use was documented by the nursing staff and total perioperative consumption was calculated based on morphine milligram equivalents (MME) described by the Centers for Disease Control and Prevention \[[@hnx050-B32], [@hnx050-B33]\]. Pain scores were not standardized during this time in the PACU and were not retrospectively reviewed due to variations in nursing documentation.

![LIA administration via spinal needle placed just anterior to the hip capsule.](hnx050f1){#hnx050-F1}

Preoperatively, all patients received oral acetaminophen (975 mg), celecoxib (400 mg), pregabalin (150 mg) and tapentadol (100 mg) as part of our standard multimodal pain medication regimen at our institution \[dosages varied appropriately with patient weight and body mass index (BMI)\]. Patients in the intervention group received a 20-ml injection of 0.25% bupivacaine--epinephrine (1 : 200 000) in the tissue adjacent to the hip capsule after capsular closure had been performed. This was performed under direct visualization prior to closure of the portals. Patients in the control group did not receive an LIA injection. All surgical procedures were carried out by the senior author (SKA).

Postoperatively, patients were monitored in the PACU by nursing staff and their pain was addressed using primarily oral or intravenous (i.v.) pain medication per nursing staff discretion. If the patient's pain was considered to be inadequately addressed using prescribed pain medications by both the nursing staff and the anesthesiology team, then a postoperative nerve block was performed by the anesthesiology team. Postoperative nerve blocks consisted of 25--50 ml of 0.25% bupivacaine with 5 μg/ml epinephrine with or without 4--8 mg dexamethasone.

Demographics, clinical characteristics and outcomes of interest were compared between LIA and non-LIA patient groups. Categorical variables were described in frequency and percentage, and were compared using a chi-squared test. Continuous variables were compared using a *t*-test or Wilcoxon--Mann--Whitney test as appropriate. All statistical analysis was performed using SAS 9.4 (SAS Institute Inc., Cary, NC, USA).

RESULTS
=======

There were no significant differences in gender, age or prior opioid use between the LIA and non-LIA groups. All baseline characteristics can be found in [Table I](#hnx050-T1){ref-type="table"}. In the non-LIA group, 39 patients underwent femoracetabuloplasty with labral repair and 11 patients underwent femoracetabuloplasty without labral repair. In the LIA group, 40 patients underwent femoracetabuloplasty with labral repair, 8 patients underwent femoracetabuloplasty without labral repair, 1 patient underwent femoracetabuloplasty with lesser trochanteric osteochondroplasty and psoas tendon repair, and 1 patient underwent capsular repair and reconstruction using a MaxForce GraftJacket (Wright Medical Technology, Memphis, TN, USA). Table I.Patient demographics and clinical characteristicsCharacteristicsLIA (*N* = 50)Non-LIA (*N* = 50)*P*-valueSex, *n* (%) Male14 (28)18 (36)0.39[^a^](#tblfn2){ref-type="table-fn"} Female36 (72)32 (64)Surgery duration, hours, mean (SD)2.03 (0.49)2.02 (0.52)0.87[^b^](#tblfn3){ref-type="table-fn"}PACU duration, hours, mean (SD)2.52 (1.17)2.33 (0.71)0.34[^b^](#tblfn3){ref-type="table-fn"}BMI Mean (SD)25.47 (5.52)25.09 (5.71) Median (IQR)21.29 (24.15, 26.51)21.29 (24.15, 26.51)0.71[^c^](#tblfn4){ref-type="table-fn"}Age at surgery, years, mean (SD)37.44 (11.59)33.64 (11.97)0.11[^b^](#tblfn3){ref-type="table-fn"}Prior opioid use, *n* (%) No44 (88)39 (78)0.18[^a^](#tblfn2){ref-type="table-fn"} Yes6 (12)11 (22)Prior psych meds, *n* (%) No36 (72)42 (84)0.15[^a^](#tblfn2){ref-type="table-fn"} Yes14 (28)8 (16)Side of surgery, *n* (%) Left21 (42)16 (32)0.30[^a^](#tblfn2){ref-type="table-fn"} Right29 (58)34 (68)[^1][^2][^3][^4]

There was a lower rate of PACU femoral nerve blocks in the LIA group versus the non-LIA group (0.34 versus 0.56, *P* = 0.027). However, there was no significant difference in PACU opioid consumption between the LIA and non-LIA groups (*P* = 0.740), who both consumed \>14 MME during their stay in the PACU ([Table II](#hnx050-T2){ref-type="table"}). Table II.Outcomes comparisonOutcomesLIA (*N* = 50)Non-LIA (*N* = 50)*P*-valueNerve block, *n* (%) No33 (66)22 (44)**0.027**[^a^](#tblfn6){ref-type="table-fn"} Yes17 (34)28 (56)PACU opioid use: MME, mean (SD)14.51 (9.73)14.08 (9.06)0.740[^b^](#tblfn7){ref-type="table-fn"}[^5][^6][^7]

DISCUSSION
==========

The results of this study supported our hypothesis that extracapsular LIA would significantly reduce the rate of elective postoperative femoral nerve blocks. However, the statistically equivalent PACU opioid consumption between study groups seemed to contradict the decreased use of femoral nerve blocks in the LIA group. One possible explanation is that the higher rate of nerve blocks in the control group confounded the opioid consumption findings, as patients who receive femoral nerve blocks are known to consume less opioids postoperatively \[[@hnx050-B4]\].

Importantly, the preoperative use of opiate medications, as well as psychiatric medications, was equivalent between our study groups, eliminating a potential confounding factor. Although we did not directly measure the effects of prior opioid use on perioperative pain control, the negative effects of prior chronic opioid use on both immediate and longer term postoperative pain control have been well documented \[[@hnx050-B34], [@hnx050-B35]\].

Our findings add to the current literature supporting the potential postoperative pain relief with LIA. Garner *et al.* compared postoperative numeric pain scores in hip arthroscopy patients who received a portal LIA at the end stages of surgery versus a preoperative fascia iliaca compartment block (FICB). Both groups received 40 ml of 0.125% levobupivacaine for their respective injections. During an interim analysis, with 46 of 74 planned patients having been recruited, the mean pain score at 1 h postoperatively for the LIA group was 3.4 versus 5.5 for the FICB group (*P* = 0.02); enrollment in the study was subsequently stopped \[[@hnx050-B36]\]. Previous studies have shown the FICB block to be effective in controlling pain following hip fractures \[[@hnx050-B37]\] as well as hip arthroscopy procedures \[[@hnx050-B38]\]. However, the study by Garner demonstrated that portal LIA may be even more efficacious than the FICB block, though this was within a limited cohort.

LIA strategies include both intra-articular and periarticular delivery. One concern regarding intra-articular injections is the potential chondrotoxic effects with intra-articular administration \[[@hnx050-B39]\]; however, recent *invivo* animal models have failed to substantiate this \[[@hnx050-B44], [@hnx050-B45]\]. Consequently, there is interest in utilizing a periarticular injection to avoid the potential complication of chondrolysis. Two studies have compared postoperative pain relief with intra-articular versus periarticular LIA in hip arthroscopy patients. Shlaifer *et al.* utilized a pre-emptive block strategy for hip arthroscopy administering 20 ml of 0.5% bupivacaine with epinephrine in either the periarticular region or intra-articularly at the start of surgery. The patients who received a periacetabular block experienced significant reduction in their postoperative pain at 30 min and 18 h compared with those who received the intra-articular block, whereas there was no difference in pain scores at other time points \[[@hnx050-B46]\]. In a similar study, Baker *et al.* compared hip arthroscopy patients who received either an intra-articular injection of bupivacaine or an injection of bupivacaine around the portal sites at the time of closure. At 1 and 2 h after surgery, there was no significant difference in Visual Analogue Scale pain between groups; however, at 6 h the portal LIA group had significantly less pain. Conversely, in the period immediately following surgery the portal LIA group required significantly more rescue analgesia \[[@hnx050-B47]\].

In this study, 0.25% bupivacaine--epinephrine was injected under direct visualization into the tissue directly anterior to the hip capsule following capsular closure. We chose to target the capsule directly as it is known to be highly innervated \[[@hnx050-B29], [@hnx050-B31]\] and contain nociceptive fibers \[[@hnx050-B31]\], making it a likely pain generator in hip arthroscopy. Therefore, the rationale of this approach to LIA in the hip is that it avoids potential chrondrolysis, while still targeting the most likely source of pain.

This study had several limitations, including the retrospective design and limited sample size. The hip arthroscopy and LIA procedures were carried out by a single-surgeon, which questions reproducibility. However, the LIA extracapsular injection is easily reproducible from a technical standpoint and the lack of multiple surgeons decreases variability in overall surgical technique. Although our PACU staff currently operate within a standardized protocol, nursing staff still exercise discretion in their administration of oral and i.v. pain medications, leading to inevitable variability across staff members. Standardized pre- and postoperative pain scores were not routinely collected during this study period, which would have allowed for more complete analysis, especially concerning which pain levels were associated with block decision, opioid consumption, etc. A patient's decision to get a nerve block is multi-faceted and may not accurately reflect their pain level. Consequently, our results do not necessarily reflect actual pain levels experienced by the patient, but rather their utilization of pain management modalities. Finally, as the senior author began performing periarticular LIA in all patients after a certain time point, there is potential for other confounding factors with changes in surgical technique over time; however, no identifiable changes in technique were employed during the study time. During the study period, we elected to use 20 ml of 0.5% bupivacaine with epinephrine, as bupivacaine was the most cost efficient, long-acting local anesthetic available. We also selected a volume of 20 ml in order to allow for our block team to have the option of performing a nerve block in the immediate postoperative period if requested. We have since increased the volume of the extra-capsular injection to 30 ml of 0.5% bupivacaine with epinephrine.

The described use of LIA in this study is a low-cost and simple approach to manage postoperative pain in hip arthroscopy patients, taking advantage of the direct visualization of the joint capsule and needle placement at the end of the arthroscopic procedure. The decreased rate of postoperative nerve blocks suggests that an extracapsular LIA injection may be an effective tool in the postoperative pain management of hip arthroscopy patients.
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